Healthcare Services

Opioid-Induced Constipation Treatment Market Future Outlook Showing Expansion Toward $2.54 Billion by 2030

April 3, 2026April 6, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Will The Market Size Of The Opioid-Induced Constipation Treatment Market Evolve From 2026 To 2030?

The opioid-induced constipation treatment market has demonstrated substantial growth in recent years. It is anticipated to increase from $1.9 billion in 2025 to $2.02 billion in 2026, with a compound annual growth rate (CAGR) of 6.7%. The expansion observed historically can be attributed to several factors including the widespread administration of opioids for managing chronic pain, the limited effectiveness of traditional laxatives, the escalating prevalence of pain associated with cancer, the previous absence of early therapies specifically for OIC, and a rise in hospitalizations resulting from opioid-related adverse effects.

The opioid-induced constipation treatment market is anticipated to show significant expansion in the upcoming years. This market is projected to reach $2.54 billion by 2030, progressing at a compound annual growth rate (CAGR) of 5.9%. The anticipated expansion over the forecast period is primarily driven by the escalating demand for PAMORA-based therapies, the growing number of long-term opioid prescriptions for aging populations, an increasing clinical emphasis on patient-centered pain management, wider access through online and retail pharmacies, and greater investment in developing drugs for gastrointestinal disorders. Significant trends during this period are expected to involve the increasing uptake of peripherally acting µ-opioid receptor antagonists, a growing preference for targeted OIC treatments that do not compromise pain relief, an expanded application of combined pharmacological and non-pharmacological interventions, an elevated focus on enhancing the quality of life for chronic pain patients, and improved awareness and diagnosis of opioid-induced constipation.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15881&type=smp

Which Growth Drivers Are Contributing To The Progress Of The Opioid-Induced Constipation Treatment Market?

The projected growth of the opioid-induced constipation treatment market is linked to the increasing use of opioids for both cancer and non-cancer pain. Cancer pain refers to discomfort experienced due to cancer and its treatments, while non-cancer pain originates from conditions unrelated to cancer. Opioids are administered to effectively manage moderate to severe pain, considering aspects such as pain intensity and duration, patient response to other therapies, and the overarching goal of enhancing quality of life while minimizing potential addiction risks and side effects. Opioid-induced constipation (OIC) treatment offers relief to patients with cancer and non-cancer pain by alleviating constipation caused by opioid use, thereby improving overall comfort, adherence to pain management regimens, and quality of life without compromising pain relief. For instance, according to the Centers for Disease Control and Prevention, a US-based public health agency, in November 2024, the rate of opioid prescriptions dispensed in 2023 was 37.5 per 100 persons. Furthermore, states reporting the highest opioid dispensing rates per 100 persons in 2023 included Arkansas (71.5), Alabama (71.4), Mississippi (63.1), and Louisiana (62.7). Consequently, the rising administration of opioids for cancer and non-cancer pain is driving the expansion of the opioid-induced constipation treatment market.

Which Segment Areas Are Covered In The Opioid-Induced Constipation Treatment Market Analysis?

The opioid-induced constipation treatment market covered in this report is segmented –

1) By Drug Class: Laxatives, Peripherally Acting µ-opioid Receptor Antagonists, Serotonin Receptor Agonists

2) By Type: Oral, Parenteral

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies

Subsegments:

1) By Laxatives: Osmotic Laxatives, Stimulant Laxatives, Bulk-Forming Laxatives

2) By Peripherally Acting µ-Opioid Receptor Antagonists: Naloxegol, Methylnaltrexone, Alvimopan

3) By Serotonin Receptor Agonists: Prucalopride, Tegaserod

How Are Trends Shaping The Direction Of The Opioid-Induced Constipation Treatment Market?

Major companies in the opioid-induced constipation treatment market are focusing on developing innovative solutions, such as peripherally acting µ-opioid receptor antagonists (PAMORAs). These are designed for targeted modulation of gut receptors, aiming to increase efficacy, improve patient compliance, and reduce systemic side effects during opioid therapy. A PAMORA functions by selectively blocking µ-opioid receptors in the gastrointestinal tract without crossing the blood–brain barrier, thereby restoring bowel function while maintaining central analgesia. This mechanism differs from traditional laxatives, which do not address the fundamental receptor-mediated cause of constipation. For example, in May 2025, Luye Pharma, a China-based pharmaceutical company, launched Mimeixin, an oral oxycodone/naloxone sustained-release tablet specifically for OIC. This product provides once-daily analgesia while antagonizing gut opioid receptors, leading to improved bowel regularity and reduced gastrointestinal side effects compared to older therapies, offering patients a convenient alternative that combines pain control and constipation management in a single tablet.

Which Global Companies Are Actively Competing In The Opioid-Induced Constipation Treatment Market?

Major companies operating in the opioid-induced constipation treatment market are Pfizer Inc., AstraZeneca plc, Takeda Pharmaceutical Company Limited, Bausch Health Companies Inc., Ironwood Pharmaceuticals Inc., Collegium Pharmaceutical Inc., Cumberland Pharmaceuticals Inc., RedHill Biopharma Ltd., Theravance Biopharma Inc., Mundipharma International Limited, Daiichi Sankyo Co Ltd, Progenics Pharmaceuticals Inc, Shionogi & Co Ltd, Purdue Pharma, Nektar Therapeutics, S L A Pharma AG, Bristol-Myers Squibb Company, Fresenius Kabi AG, Viatris Inc, Novartis AG, Teva Pharmaceutical Industries Ltd, F Hoffmann-La Roche Ltd, Aurobindo Pharma, Abbott Laboratories, Daewoong Pharmaceutical Company

Read the full opioid-induced constipation treatment market report here:

https://www.thebusinessresearchcompany.com/report/opioid-induced-constipation-treatment-global-market-report

What Are The Leading Geographic Regions In The Opioid-Induced Constipation Treatment Market?

North America was the largest region in the opioid-induced constipation treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the opioid-induced constipation treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Opioid-Induced Constipation Treatment Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=15881&type=smp

Browse Through More Reports Similar to the Global Opioid-Induced Constipation Treatment Market 2026, By The Business Research Company

Opioids Global Market Report

https://www.thebusinessresearchcompany.com/report/opioids-global-market-report

Opioid Induced Constipation Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/opioid-induced-constipation-treatment-global-market-report

Migraine Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/migraine-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795